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Purpose Hypertension has received too much attention because of its high prevalence, its 
association with concomitant risk factors and mortality. Considering the pathophysiology of 
hypertension and the key role of blood viscosity (BV) in the regulation of blood pressure (BP), 
and also hemorheological effects and cardiovascular benefits of pentoxifylline (PTX), this study 
was conducted to evaluate whether PTX can reduce BP when added to captopril in patients with 
stage 1 hypertension. 
 
Methods In this pilot randomized clinical trial 62 patients at the age of 18 to 80, with diagnosis 
of stage 1 hypertension were entered. The intervention group (n=30) received 1200 mg PTX in 
three divided doses plus 25 mg captopril three times a day whereas, the control group (n=32) 
received only 75 mg captopril in three divided doses. Measurements of BP were done according 
to American Heart Association (AHA) guidelines at baseline, first and second month of the 
study period. Major adverse cardiac events (MACEs) during this period were recorded as 
secondary end points of the study. 
 
Results Comparing the systolic blood pressure (SBP) levels in the groups of intervention and 
control no significant differences were noted at baseline (150.4±6.03 vs.150.4±6.2, p=0.98), 
first (138.4 ±9.4 vs. 142.3 ±5.6, p=0.08) and second (134.6 ±8.9 vs. 137.4±6.0, P=0.20) months 
of the study respectively. Similarly, no significant differences were observed in the diastolic 
blood pressure (DBP) at baseline (91.7±3.9 vs. 92.0 ±3.7, p=0.84), first (85.5±5.1 vs. 86.9 ±3.8, 
p=0.27) and second (82.6 ±5.7 vs. 84.0 ±3.5, p=0.31) months. About baseline demographic data 
of patients, no significant differences were observed between the two groups. 
 
Discussion and Conclusions Based on the results of present study, adding PTX as a 
hemorheological agent to captopril could not significantly reduce blood pressure in the patients 
with stage 1 hypertension. Our findings are in accordance with previous studies however, they 
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ACE: Angiotensin Converting Enzyme 
ANS: Autonomic Nervous System 
ARB: Angiotensin II Receptor Blockers                                       
BP: Blood Pressure 
BV: Blood Viscosity 
cAMP: cyclic Adenosine Mono Phosphate 
CCBs: Calcium Channel Blockers 
CHD: Coronary Heart Disease 
Chl: Cholesterol 
CKD: Chronic Kidney Disease 
CVD: Cardio Vascular Disease 
CO: Cardiac Output 
DBP: Diastolic Blood Pressure 
GFR: Glomerular Filtration Rate  
FBS: Fasting Blood Sugar                                                            
HDL: High Density Lipoprotein                                                      
Hgb: Hemoglobin 
LDL: Low Density Lipoprotein                                                   
LVH: Left Ventricular Hypertrophy 
PDE: Phosphodiesterase  
PTX: Pentoxifylline 
PVR: Peripheral Vascular Resistance 
RAS: Renin-Angiotensin System 
RBC: Red Blood Cell 
SBP: Systolic Blood Pressure 
sCr: serum Creatinine 




TNF-α: Tumor Necrosis Factor alpha 
TPR: Total Peripheral Resistance 
 
